

### **Blakes Private Equity Practice**

Blakes has one of the strongest and most experienced private equity practices in Canada. As a national team, we drive innovative transactional structures and their strategic implementation, with a depth of industry knowledge and perspectives from across the country.

Our Private Equity team spans various specialty areas, including M&A, capital markets, competition, foreign investment review, tax, financial services, real estate, intellectual property, pensions, benefits and executive compensation. We provide strategic advice and legal counsel at each stage of the investment lifecycle: fund formation, fund management and governance, financing, acquisitions and investments, management of portfolio companies, and exit strategies.

For more information on our Private Equity practice, visit www.blakes.com.

# Contents

01	Overview	01	06	Closing Conditions	29
<b>-</b>	1.1 Foreword	02		6.1 R&W Bring Down	30
	1.2 Focus	03		6.2 No Material Adverse Change	3.
	1.3 Snapshot	04		6.3 Competition Act Approvals	32
	1.4 Players	05		6.4 Other Conditions	33
	1.5 Dynamics	06			
			07	Indemnification	34
02	Process	07	07	7.1 Damages Covered	35
	2.1 Interim Period	08		7.2 Survival of R&W	36
	2.2 Management Rollover	09		7.3 Stand-Alone Indemnities	39
	2.3 Options	10		7.4 Sandbagging	4(
	2.5 Options	10		7.5 Other Limitations	4
				7.6 Remedies	42
				7.7 Materiality Scrapes	43
03	Financial Terms	11		7.8 Eligible Claim Thresholds	44
				7.9 Baskets	45
	3.1 Escrows	12		7.10 Caps – General R&Ws	4
	3.2 Earnouts	15		7.11 Exclusions from Monetary Limitations	49
	3.3 Purchase Price Adjustments	17		,,,,,,,	
			00	Other	5(
04	Qualifiers	19	80		
	4.1 Definition of Material Adverse Effect	20		8.1 Interim Period Covenants	5.
	4.2 Definition of Knowledge	21		8.2 Termination Fees and Expenses	54
				8.3 Dispute Provisions	5!
				8.4 Miscellaneous	56
				8.5 R&W Insurance	57
05	Representations and Warranties (R&Ws)	22			
	5.1 Noteworthy R&Ws	23			
	5.2 Fundamental R&Ws	25	00	Blakes Private Equity	59
	5.3 Ringfencing	27	09	• •	
	5.4 Disclosure Schedule Update	28		9.1 Representative Matters	60

01

Overview

## **Foreword**

This third edition of our Canadian Private Equity Deal Study proved to be both the most volatile and expansive version to date, as it captures what was an initially uncertain yet surprisingly short pause in market activity due to COVID-19 during the spring of 2020, as well as the rapid return to deal-making that followed, which has not relented since. Deal terms were initially continuously tested and updated — from forensic scrutiny of MAE clauses to lengthening of interim periods and a refashioning of earnouts — before returning to a new normal. What was true before COVID and remains the case now includes, at least, the following: first, Canadian private equity is robustly healthy and growing and second, this Study represents the most in-depth analysis of Canadian private equity buyout and investment transactions in the legal industry, allowing for the identification of recent trends and developments and an understanding of "what is market" in Canadian private equity.



## **Focus**

#### **Private Equity Nucleus**

Unlike private M&A deal studies that source their data from publicly available sources such as SEDAR\* and are, therefore, based on private transactions involving public companies, this Study focuses on transactions involving private equity funds, sponsors or portfolio companies as sellers, buyers, investors and/or targets. Among the many novel perspectives presented in this Study is a focus on differences in dynamics and terms between domestic and cross-border deals and those involving founders or strategic companies opposite private equity investors.

#### Canadian Nexus

This Study focuses solely on transactions involving Canadian private companies or their assets.

#### **Blakes Involvement**

This Study is a proprietary analysis of Canadian buyout and minority investment transactions in which Blakes was involved. Derived from our exclusive database containing hundreds of precedents, this Study examines over 100 transactions signed between 2017 and 2020. By reporting aggregated data, we ensured no confidential information is disclosed

#### **Data Presentation**

Medians are used instead of means to eliminate distortion to averages resulting from outliers. Due to rounding, actual figures may be plus or minus 1%. In most cases, percentages have been rounded to the nearest whole percentage. Unless otherwise stated, monetary values are presented in Canadian dollars. Portfolio companies are included among private equity parties. Transactions include buyouts and minority investments.

#### **Transaction Terms**

Where transaction terms are not directly comparable, we used our judgment and discretion in summarizing, categorizing and reflecting them in this Study. The results do not reflect the views of Blakes. and accordingly, whether or not a specific term is appropriate for any transaction depends on, and merits close consideration based on, the facts and circumstances of such transaction

### Legend



**Upward Trend** 



Downward Trend



Insiaht



Explanatory



Informative




Subset




COVID-19

<sup>\*</sup> SEDAR is the System for Electronic Document Analysis and Retrieval maintained on behalf of the Canadian securities regulatory authorities for use by reporting issuers.

# **Snapshot**






## Industry



# **Players**


### Sellers






<sup>&</sup>lt;sup>1.</sup> Excludes management where management team members are also sellers.


### **Buyers**





<sup>&</sup>lt;sup>2</sup> Reflects syndicates of non-controlling sellers.

# **Dynamics**



## Get the big picture.

To request the complete Study, email gary.nurse@blakes.com.

